Context Therapeutics Inc CNTX
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-20 |
| Shares Out. | 91,880,000 |
| Website | contexttherapeutics.com/ ↗ |
| Phone | 12672257416 |
| Employees | 15 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$14.6M |
| Free Cash Flow | -$34.0M |
| Total Assets | $46.1M |
| Total Liabilities | $8.0M |
| Equity | $38.2M |
About Context Therapeutics Inc
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Context Therapeutics Inc is a publicly traded company under the ticker symbol CNTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-09-01)